Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints

References

• Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, et al. 2010. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 363(1):24–35.
   PubMed Web of Science ®Google Scholar
• Ang KK, Sturgis EM. 2012. Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma. Semin Radiat Oncol. 22(2):128–142.
   PubMed Web of Science ®Google Scholar
• Bartek J, Lukas C, Lukas J. 2004. Checking on DNA damage in S phase. Nat Rev Mol Cell Biol. 5(10):792–804.
   PubMed Web of Science ®Google Scholar
• Bridges KA, Chen X, Liu H, Rock C, Buchholz TA, Shumway SD, Skinner HD, Meyn RE. 2016. MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Oncotarget. 7(44):71660–71672.
   PubMedGoogle Scholar
• Bridges KA, Hirai H, Buser CA, Brooks C, Liu H, Buchholz TA, Molkentine JM, Mason KA, Meyn RE. 2011. MK-1775, a novel Wee1 kinase inhibitor, radiosensitizes p53-defective human tumor cells. Clin Cancer Res. 17(17):5638–5648.
   PubMed Web of Science ®Google Scholar
• Bridges KA, Toniatti C, Buser CA, Liu H, Buchholz TA, Meyn RE. 2014. Niraparib (MK-4827), a novel poly(ADP-Ribose) polymerase inhibitor, radiosensitizes human lung and breast cancer cells. Oncotarget. 5(13):5076–5086.
   PubMed Web of Science ®Google Scholar
• Busch CJ, Kriegs M, Laban S, Tribius S, Knecht R, Petersen C, Dikomey E, Rieckmann T. 2013. HPV-positive HNSCC cell lines but not primary human fibroblasts are radiosensitized by the inhibition of Chk1. Radiother Oncol. 108(3):495–499.
   PubMed Web of Science ®Google Scholar
• Busch CJ, Kroger MS, Jensen J, Kriegs M, Gatzemeier F, Petersen C, Munscher A, Rothkamm K, Rieckmann T. 2017. G2-checkpoint targeting and radiosensitization of HPV/p16-positive HNSCC cells through the inhibition of Chk1 and Wee1. Radiother Oncol. 122(2):260–266.
   PubMed Web of Science ®Google Scholar
• Carugo A, Genovese G, Seth S, Nezi L, Rose JL, Bossi D, Cicalese A, Shah PK, Viale A, Pettazzoni PF, et al. 2016. In Vivo functional platform targeting patient-derived xenografts identifies WDR5-Myc association as a critical determinant of pancreatic cancer. Cell Rep. 16(1):133–147.
   PubMed Web of Science ®Google Scholar
• Chalmers AJ, Lakshman M, Chan N, Bristow RG. 2010. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Semin Radiat Oncol. 20(4):274–281.
   PubMed Web of Science ®Google Scholar
• Demers GW, Foster SA, Halbert CL, Galloway DA. 1994. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. PNAS. 91(10):4382–4386.
   PubMed Web of Science ®Google Scholar
• El-Naggar AK, Westra WH. 2012. p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency. Head Neck. 34(4):459–461.
   PubMed Web of Science ®Google Scholar
• Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al. 2005. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 434(7035):917–921.
   PubMed Web of Science ®Google Scholar
• Godon C, Cordelieres FP, Biard D, Giocanti N, Megnin-Chanet F, Hall J, Favaudon V. 2008. PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility. Nucleic Acids Res. 36(13):4454–4464.
   PubMed Web of Science ®Google Scholar
• Guster JD, Weissleder SV, Busch CJ, Kriegs M, Petersen C, Knecht R, Dikomey E, Rieckmann T. 2014. The inhibition of PARP but not EGFR results in the radiosensitization of HPV/p16-positive HNSCC cell lines. Radiother Oncol. 113(3):345–351.
   PubMed Web of Science ®Google Scholar
• Havre PA, Yuan J, Hedrick L, Cho KR, Glazer PM. 1995. p53 inactivation by HPV16 E6 results in increased mutagenesis in human cells. Cancer Res. 55(19):4420–4424.
   PubMed Web of Science ®Google Scholar
• Hickman ES, Picksley SM, Vousden KH. 1994. Cells expressing HPV16 E7 continue cell cycle progression following DNA damage induced p53 activation. Oncogene. 9(8):2177–2181.
   PubMed Web of Science ®Google Scholar
• Karam SD, Reddy K, Blatchford PJ, Waxweiler T, DeLouize AM, Oweida A, Somerset H, Marshall C, Young C, Davies KD, et al. 2018. Final report of a phase I trial of olaparib with cetuximab and radiation for heavy smoker patients with locally advanced head and neck cancer. Clin Cancer Res. 24(20):4949–4959.
   PubMed Web of Science ®Google Scholar
• Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, Han SM, Lorincz AT, Hedrick L, Cho KR. 1993. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. PNAS. 90(9):3988–3992.
   PubMed Web of Science ®Google Scholar
• Liu C, Mann D, Sinha UK, Kokot NC. 2018. The molecular mechanisms of increased radiosensitivity of HPV-positive oropharyngeal squamous cell carcinoma (OPSCC): an extensive review. J Otolaryngol Head Neck Surg. 47(1):59.
   PubMedGoogle Scholar
• McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A. 2005. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther. 4(9):934–936.
   PubMed Web of Science ®Google Scholar
• McCabe N, Turner N C, Lord C J, Kluzek K, Białkowska A, Swift S, Giavara S, O'Connor M J, Tutt A N, Zdzienicka M Z, et al. 2006. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res. 66(16):8109–8115.
   PubMed Web of Science ®Google Scholar
• Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, Grace M, Huh K. 2004. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 78(21):11451–11460.
   PubMed Web of Science ®Google Scholar
• Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y. 2012. Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 72(21):5588–5599.
   PubMed Web of Science ®Google Scholar
• Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG. 2010. PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 10(4):293–301.
   PubMed Web of Science ®Google Scholar
• Slebos RJ, Lee MH, Plunkett BS, Kessis TD, Williams BO, Jacks T, Hedrick L, Kastan MB, Cho KR. 1994. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. PNAS. 91(12):5320–5324.
   PubMed Web of Science ®Google Scholar
• Stephen JK, Divine G, Chen KM, Chitale D, Havard S, Worsham MJ. 2013. Significance of p16 in site-specific HPV positive and HPV negative head and neck squamous cell carcinoma. CCO. 2(1):51–61.
   Google Scholar
• Wang L, Mason KA, Ang KK, Buchholz T, Valdecanas D, Mathur A, Buser-Doepner C, Toniatti C, Milas L. 2012. MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs. 30(6):2113–2120.
   PubMed Web of Science ®Google Scholar
• Wang L, Wang X, Li Y, Han S, Zhu J, Wang X, Molkentine DP, Blanchard P, Yang Y, Zhang R, et al. 2017. Human papillomavirus status and the relative biological effectiveness of proton radiotherapy in head and neck cancer cells. Head Neck. 39(4):708–715.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang P, Molkentine DP, Chen C, Molkentine JM, Piao H, Raju U, Zhang J, Valdecanas DR, Tailor RC, et al. 2017. TRIP12 as a mediator of human papillomavirus/p16-related radiation enhancement effects. Oncogene. 36(6):820–828.
   PubMed Web of Science ®Google Scholar